Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

UK government announces new rare diseases action plan for England

UK government announces new rare diseases action plan for England

The framework lists 13 actions that have been developed with the rare disease community. ... One in 17 people will be affected by a rare disease at some point in their lives, such as spinal muscular atrophy, haemophilia A, epidermolysis bullosa or

Latest news

More from news
Approximately 7 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    We need to fast-track new treatments. As of last year, there are over 100 treatments in clinical trials for Alzheimer’s disease. ... The Dementia Consortium funds research into novel targets and treatments for dementia including Alzheimer’s disease,

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    to learn from its own mistakes with therapies for Huntington’s disease and also haemophilia. ... Increasingly factored into this equation is competition from companies following Bluebird into beta thalassemia and sickle cell disease.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease. ... It’s hoped it could be a big step in treatment for the genetically-inherited and rare wasting disease.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...

Quick links